HL-1186 tablets for reducing pain after abdominal surgery
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase Ⅱa Study to Evaluate the Safety and Efficacy of HL-1186 Tablets for Postoperative Pain Management in Abdominal Surgery
Run by Shanghai Huilun Pharmaceutical Co., Ltd. · NCT07311369 · Data updated 2026-11-12
This trial will test whether HL-1186 tablets reduce moderate to severe pain after abdominal surgery in adults aged 18–75.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Shanghai Huilun Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | December 2025 |
| Main results expected | February 2026 |
| Study ends | March 2026 |
| Registry record updated | December 30, 2025 |
| Trial ID | NCT07311369 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with BMI 18–30 kg/m2 who are scheduled for abdominal surgery under general anesthesia and can use pain scales and communicate with study staff are the ideal candidates.
✕Probably not a fit
Patients with prior surgery at the same site, significant cardiac disease, high bleeding risk, multiple allergies to study medications, or BMI outside the specified range are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a phase 2, randomized, double-blind, placebo-controlled, multi-center trial comparing oral HL-1186 tablets to matching placebo in adults undergoing abdominal surgery under general anesthesia. The trial will collect safety data, measure postoperative pain outcomes, and analyze pharmacokinetic (PK) parameters of HL-1186. Eligible participants are adults 18–75 years old with BMI 18–30 kg/m2 who can use pain scales and communicate with researchers. Treatments and pain scores will be monitored in the immediate postoperative period to detect differences in pain relief and adverse events.
Why it matters
Potential benefit: If successful, HL-1186 could provide better short-term pain control after abdominal surgery and potentially reduce reliance on stronger analgesics.
How similar studies have gone: Oral non-opioid analgesics have shown mixed success in randomized placebo-controlled settings, and HL-1186 represents a novel compound that has not yet been proven in larger trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years old ≤ age ≤ 75 years old, gender is not limited. 2. 18 kg/m2 ≤ Body Mass Index (BMI) ≤ 30kg/m2. 3. Scheduled to undergo abdominal surgeries under general anesthesia. 4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers. Exclusion Criteria: 1. Prior history of surgery at the same site, and this may affect pain perception at the surgical site per investigator's judgments. 2. Allergy to any component of the investigational product, to perioperative anesthetic/analgesic/antiemetic agents, or to ≥3 substance allergies. 3. Unstable angina, myocardial infarction, severe arrhythmias (e.g., third-degree atrioventricular block), New York Heart Association (NYHA) class III or higher cardiac function, recurrent asthma, etc., within screen period, and deemed ineligible per investigator's judgments. 4. High bleeding risk conditions: Congenital bleeding disorders (e.g., hemophilia), platelet function abnormalities (e.g., idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet function abnormalities), active bleeding, etc., and deemed ineligible per investigator's judgments. 5. For female participants: Pregnant or lactating (within 1 year postpartum). 6. Participants with childbearing potential planning conception/sperm/egg donation within 6 months post-treatment, or unwilling to use effective contraception (abstinence, barrier methods, oral contraceptives, intrauterine device, or sterilization). 7. Judgment by the investigator that the participant should not enter the study due to other conditions.
Where it's running
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China Recruiting
Study contacts
- Study coordinator: Renhai Yang
- Email: clinical_trial@hllife.com.cn
- Phone: 021-64311017
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HL-1186 tablets to treat moderate to severe pain after surgery.
This Phase 2 test will try HL-1186 tablets to see if they reduce moderate to severe postoperative pain in adults having elective orthopedic, abdominal, or thoracic surgery.
-
HL-1186 Tablet for postherpetic neuralgia: safety and efficacy in adults
This study tests whether HL-1186 tablets, compared with placebo and with pregabalin, help reduce pain in adults with postherpetic neuralgia.
-
HL-1186 Tablet for postoperative pain after abdominal surgery
This trial tests HL-1186 tablets to see if they reduce pain after abdominal surgery compared with placebo and an oxycodone-acetaminophen option.
-
HL-1186 Tablet for postoperative pain after orthopedic surgery
A mid-to-late phase trial tests HL-1186 tablets against placebo and standard opioid therapy to see if they can help manage pain after orthopedic surgery for adults 18–75.
-
YD0743 for sepsis-associated ARDS in adults
This trial will test whether YD0743 can shorten the number of days adults in the ICU with sepsis-associated ARDS need a ventilator and whether the drug is safe to use.
-
HTMC0658 tablets to treat chronic sinusitis without nasal polyps
This trial will test whether HTMC0658 tablets can help adults with chronic rhinosinusitis without nasal polyps feel better and have fewer sinus symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.